I Summary: In 1988, inundated by the tedious work of validation of laboratory reports in a large hospital biochemisj try laboratory, we designed VALAB, a knowledge-based system specially dedicated to this iterative function.
Introduction
In large hospital laboratories that use high throughput equipment, the task for human validation of final reports is very important, in spite of the help provided by efficient laboratory information systems. It is time consuming and highly dependent on the skill and experience of the supervisors. Therefore we decided in 1988 to use "artificial intelligence" and to carry out a knowledgebased system project to aid decision making and to perform an automated validation of data. The program was first designed for an electrolyte profile (1) but it has been rapidly expanded to handle 22 tests commonly run in the clinical chemistry laboratory (2) . Right now the system is able to deal with 45 commonly used tests. Simultaneously, new rules have been added to cope with clinical data, the final decision is improved by "weighing" rules that are used in different clinical circumstances. Moreover, in addition to its use in, the Chemical Pathology laboratory, the system has also been allocated to other disciplines of laboratory medicine, Haematology (3, 4) and Haemostaseology, where automated equipment is also operated. When this occurred, the first evaluation protocol (2) was modified and accordingly also changed in Clinical Chemistry.
Since many amendments and improvements have been introduced in the program, we have thought it would be interesting to check again and report the performance in the three disciplines of this updated version of our knowledge-based system VALAB.
Material and Methods

Material
The knowledge-based system operates on a microcomputer IBMcompatible PC (Compaq, Microdis, 31700 Blagnac, France) containing an Intel 80386 or 80486 processor, 4 megabytes of RAM, a 80-megabyte hard disk and Hercules or VGA graphics.
The software runs under MS-DOS and uses the generator (inference engine) KHEOPS (5) from the Laboratoire d'Automatique et d'Analyse des Systemes, an institute of the Centre National de. la Recherche Scientifique in France. KHEOPS uses forward chaining as the reasoning process that is applied to the knowledge base represented in the form of production rules. It is moreover able to compile the rule base. 2. The production rules (more than 20 000) represent the knowledge and are expressed in conditional (if-then) form. There are four sets or rules:
(a) The ones representing the core of the system are devoted to the various criteria selected to help decide whether to validate laboratory data. VALAB actually uses the following information for every patient data: acceptable limits, internal coherence between analyte results which are physiologically related, delta check, origin of the sample, i.e. identification of the ward and the medical speciality, "Stat" analysis or not, out or in-patient, age, sex, comments on the sample quality.
(b) Some rules (weighing rules) define dynamically acceptability thresholds for each patient, as various trends for that patient are noticed. This "qualitative reasoning" approach (5, 6 ) is a characteristics of the second generation of knowledge-based systems. There are weighing rules for instance to modify the acceptable, ranges in various analyte values or in delta check acceptance.
(c) For each test some "negative" rules have been written in order to restrict the validation of a normal value that would not be in accordance with other data. (d) particular rules cope with clinical or therapeutical data. They are of major interest and must be developed in the future. An exampie of these different rules is given in the Appendix. All these rules are divided into 100 rule groups, each rule group containing between 100 and 300 elementary rules which are related to a similar topic. An example of the strategic path used, e.g. for the validation of a high aspartate aminotransferase value, is shown in the Appendix.
Groups of rules are compiled, resulting in the construction of a decision network that can be more rapidly processed than the rules in their original form. This "pretreatment" of the internal representation of the knowledge base results in a total, inference time, which varies for each report according to the number of data, but does not exceed approximately 500 ms.
3. The evaluation protocol has been modified in order to introduce a new step: the clinical chemists' and pathologists' consensus that is the reference decision, with which either VALAB or every supervisor decision will be compared. Four MDs with specialisation in Chemical Pathology, two PhDs in pharmacy with specialisation in Clinical Biochemistry and one PhD in Clinical Chemistry for the laboratory of Clinical Chemistry and three MDs specialised in Haematology for the Laboratory of Cellular Haematology and four Clinical Pathologists in Haemostaseology were the human referees.
They had to check separately 338 patient reports in chemistry, 384 for pH and blood gases, 357 in haematology and 550 in haemostaseology. The control process was conducted along the epidemiological method used to assess the sensitivity, specificity and predictive values of a clinical symptom or a laboratory test. These values can be calculated and compared between the knowledge-based system and the human observers.
T(+) or true positive is defined as correctly stopping a wrong report, T(-) or true negative is the validation of a correct report, F(+) or false positive is the inappropriate rejection of a good report and F(-) is badly accepting an incorrect report.
Review of the formulae shows that the emphasis must be largely given to sensitivity and negative predictive value because they both contain the unacceptable F(-).
Sensitivity
(proportion of rejected incoherent reports)
Specificity
(proportion of accepted coherent reports)
Positive predictive value (proportion of incoherent reports within the rejected ones)
Negative predictive value (proportion of coherent reports within the accepted ones) T(-) + F(-) Furthermore, the system has also been submitted to a national multicentric evaluation in five different laboratories, with 4 large hospital laboratories of clinical chemistry and 1 big private laboratory of clinical pathology, representing a total of 19 referees.
4. Statistical data are available concerning the activity and the performance of VALAB within the various laboratories of our hospital, with emphasis on results that are considered invalid, and which must be viewed by the user along with the reasons given by the system for the rejection.
Results
Data from the evaluation protocols and from the statistical activities are presented here.
Evaluation results
In Clinical Chemistry
In. this study 338 reports were included. The VALAB decisions on the one hand and the human ones on the other were both compared to the collegial decision, defined as the consensus of the various supervisors. Data are presented in table 3.
The various steps were (a) to check first the 338 reports within a single period of time for each of the seven supervisors in order to consider the tiring effect of such a batch of results to be validated. Fifty seven reports showed discrepancies between the various supervisors and needed a search for consensus which was easily met.
(b) Taking into account this consensus decision, two reports accepted by VALAB but previously blocked by the medical staif were thus accepted and therefore 2 F(-) moved to 2 T(+); and twenty nine reports validated by the staff but firstly rejected by VALAB were accepted by the system after some modifications in the "weighing" rules, resulting in 29 F(+) becoming 29 T(-) T(-) (c) To improve the system performance again, we adjusted some upper limits and accordingly the VALAB final decision was to reject four reports that were previously accepted, 4 F(-) becoming 4 T(+), and to accept nine cases rejected before the correction, 9 F(+) moving to 9 T(-).
With these last figures, sensitivity, specificity and predictive values were calculated again, showing a sensitivity of 100% and a negative predictive value of 100%; these are the main values to consider because there is F(-) in their definition and we cannot accept a system that inappropriately validates a wrong report.
T(+) + F(+)
Multicentric evaluation in Clinical Biochemistry
T(-) Data were collected under the same conditions within the various selected laboratories at the national level. VALAB was connected to different Laboratory Information Systems and 1675 reports were examined.
The general conclusions are presented in table 4. In four laboratories 38.5% of the reports accepted by the medical staff were also validated by VALAB, except in one hospital laboratory dealing only with emergency testing for very severe diseases and without previous results, where the knowledge-based system accepted only 5% of the 65% validated by the staff.
In haematology
The evaluation was performed by three clinical pathologists on 357 reports randomly selected from the file of reports needing a medical validation.
As in the clinical chemistry protocol, we performed the first individual validation with the fatigue effect for human observation.
Some reports were then modified after consensus, finally producing VALAB's validation after amendment of some parameters for best fit with the pathologists' consensus, which is considered as the ideal decision.
Between the first two steps, 89 reports produced variable decisions amongst the three pathologists, necessitating a consensus that was met easily, except for 5 reports which were therefore withdrawn.
All these data are presented in table 5.
In haemostaseology
The evaluation was performed by four MDs who compared their decision for 550 reports with that of the VALAB. The same protocol was again used and gave the following results:
111 reports needed a consensus, 94 lacking agreement from the four pathologists, 17 being blocked by VALAB and accepted by the medical staff (F(+)). There was no F(-) in the expert system analysis.
After consensus decision and modification of some parameters and some weighing data in VALAB's program, the final calculation was excellent and gave 1.00 for sensitivity and negative predictive value, with no residual F(-).
pH and blood gases
The protocol covered 384 reports. During the first VALAB's run we noted 7 F(-) and 71 F(+) most of them, 51, due to a very high pO 2 caused by oxygenotherapy. After the consensus meeting, the acceptable limits for pO 2 were modified and the 7 F(-) became 7 T(-). We decided also to ask the intensive care units to mention the oxygen therapy on the request forms, this
Tab. 3 Epidemiological data for the three step evaluation of the (b) is the result obtained after consensus. expert system VALAB in clinical biochemistry.
(c) is the final decision of VALAB after modification of some (a) is the primary comparison between VALAB and seven superviparameters taking into consideration the consensus decision. sors. (b) is the result obtained after consensus.
(c) is the final decision of VALAB after modification of some parameters taking into consideration the consensus decision. information being therefore taken into consideration by the knowledge-based system.
Statistical data concerning routine operation
The three laboratories are using VALAB for a round the clock service.
The reports submitted to the expert system are not identical, and they vary according to the discipline.
In Chemical Pathology the system examines only the reports already blocked for any abnormality by the laboratory information system and then stored in a special file of reports to be validated. VALAB regularly explores this file and, according to its knowledge, either rejects or validates the reports, which are, in this case, immediately sent through the hospital network and printed out. The remaining reports, with indication of the reason for VALAB's rejection, are reviewed on the screen of the laboratory information system by the medical staff.
In Haematology and Haemostaseology, entire reports may be considered as abnormal by the laboratory information system and thus VALAB has to expertise all the data stored in the file.
An example of the activity of the knowledge-based system during a relative quiet fortnight of July 1995 is given in table 6.
Discussion
VALAB can be considered as a screening program dedicated to the automated selection of reports needing a human view, in order to either accept them as valid or have them rerun or, mainly in Haematology or Haemostaseology, have them checked comprehensively with dialogue with the physician.
It was most important, of course, to perform a very strict evaluation to check the adequateness of VALAB expertise before the routine implementation of such an automated process. The method used for the evaluation is derived from the epidemiological protocols. It gave satisfactory results after addition of the consensus step, which represents ideal decision from the medical point of view.
We did not strictly follow Miller's proposal (8) who distinguished three levels of evaluation: evaluation of research contribution, validation of knowledge and performance, evaluation of the clinical efficacy of the operational system, because we limited our protocol to steps 2 and 3.
Actually, VALAB is not a clinical system to be used by physicians for interpretation of laboratory data or support for diagnosis. It is rather a tool for senior clinical chemists or pathologists remaining within the laboratory.
The only data available for evaluation of knowledgebased systems are clinical data for the performance of knowledge-based systems in their support of the interpretation of laboratory findings (9) . The strategy used by Wyatt (10) is to answer the following questions:
i) is the system wanted and of good quality? (structure),
ii) is the system pleasant to use and does it reason appropriately? (reasoning process),
iii) does it say sensible things and draw valuable conclusions? (outcome); and the means of attaining this goal are peer review and field trials.
We may consider that we have attained these objectives, because VALAB is now spread over 35 European laboratories, and because in our hospital, since 1988, we have never had any question or argument from the clinicians related to the patient reports validated by the knowledge-based systems.
VALAB has now incorporated second generation concepts (6, 7) and is able to weigh its decision according to various predefined items.
The conditions of operation can be selected within the main frame computer (laboratory information system) to which the knowledge-based system is connected as an analytical instrument; it can be as to examine either only pathological reports or any report if the limits of normality are strictly narrowed.
VALAB has been designed as a tool for helping in the tedious and iterative process of final medical validation, and all the laboratories in Europe equipped with this decision support program are using it for this task in the clinical chemists' or pathologists' office. However, it is obvious that many laboratories are limiting their validation at the bench, where they perform sophisticated pro- cess, using quality control, delta-check, mean of normals appreciation as part of the technical validation. It is therefore interesting to consider whether VALAB cannot move to the bench, become embedded in the advanced instrument workstation, and interface between high throughput equipment and laboratory computer. Such a development would seem imminent, particularly within the "Openlabs" project of the European Community (11, 12) .
Whatever the location of VALAB within the laboratory, one advantage must be emphasised, i.e. the improve·m ent of turn around time due to a rapid check and often validation of abnormal reports without waiting for a human decision. The application to various disciplines where automated equipment provides a high volume of data should also be mentioned, the program for immunoanalysis being presently under development.
Concerning the ethical problem, we have to remember that VALAB is an aid to the decision maker, and is not intended to supplant him (her); actually it represents a cooperative effort of man and machine (13 (2-4) . The analytical performance of ES 300 and ES 600 systems in smaller pilot studies has been Samples reported (5, 6) .
The multicentre evaluation was performed in 23 laboratories. The tumour markers were measured in 4266 human serum samples. In this study we compare results for the determination These samples were obtained from local patients (N = 2170) durof carcinoembryonic antigen (CEA), the cancer antigens All kits were taken from current production batches. The assays were performed according to the manufacturer's instruction. All laboratories were equipped with the fully automated Enzym-Test® System ES 300 or ES 600/700. 
Infra-assay precision
Native patient samples were analysed 10 times in one series. The mean (x), the standard deviation (S. D.) and the coefficient of variation (CV%) were calculated.
inter-assay precision
The tumour marker controls were analysed as single determinations in 3-5 different series. The mean, S.D. and CV% were calculated.
Interlaboratory survey
The samples TM 2/92 A and B were determined as one single determination. The medium and scatter (given as the 16th and 84th percentiles) of both samples A and B of all results were calculated for each analyte.
Comparison studies
Patient samples were measured using the Boehringer Mannheim enzyme immunoassay in parallel with the routine method of each laboratory. Correlation was calculated using the method of Passing & Bablok (7) .
Reference values
Sera from healthy subjects (blood donors, hospital staff) were assayed and the 95 and 99 percentiles of the results of each tumour marker were calculated.
Sensitivity of CEA, CA 19-9 and CA 72-4
In gastric cancer, colorectal cancer and pancreatic cancer the sensitivity was calculated at the 95th and 99th percentile of healthy subjects. The same calculations were performed using the reference values based on benign gastrointestinal disease. Significance was calculated using Fisher's exact test.
Results
Intra-assay precision
Every institute performed the determinations on patient samples containing different levels of markers. A target coefficient of variation of less than 5% was reached in 80% of all serum samples including all tumour markers (111 out of 139 = 80%). In serum samples starting at the cut-off level or higher, a coefficient of variation of less than 5% was confirmed in 72 out of 76 samples (95%). All tumour markers showed the same pattern. Examples are given in figures 1 and 2, for CA 19-9 and Cyfra 21-1, respectively.
Inter-assay precision
The target coefficient of variation of less than 10% was confirmed in 86% of all series (N = 120 for the total of the two tumour marker control levels). The inter-assay precision of the tumour marker control levels were determined according to the evaluation protocol. In tables 1 and 2 the range of the inter-assay coefficient of variation of the different markers are represented together with the number of participating laboratories. Also the mean of the coefficient of variation in the different laboratories was calculated. This was between 5.9% and 9.6% using the low control and between 3.9% and 7.2% using high control. Also the number of laboratories with a coefficient of variation of less than 10% is indicated. The lowest mean CV% was found for AFP and the highest for CA 72-4 in both controls. > f [ Interlaboratory survey
The results for the assayed tumour markers in samples A and B, which were provided by the German Society for Clinical Chemistry (8), were compared with the results obtained in the 'German Ringversuch 1992' using the Boehringer Mannheim Assays. The results are summarized in tables 3a and b. An example is given for CA 19-9 in figure 3 . The coefficient of variation was around 13% in the present study (13 laboratories) as compared with around 17% in the 'German Ringversuch 1993' (47 laboratories).
Method comparison studies
In 29 cases results obtained with the ES 300 or the ES 600/700 were compared with those from one of the other methods as performed routinely in the institute (see the section Assays). As examples, the results are presented for CA 15-3 (using the same antibodies) and for CEA (using different antibodies). In three laboratories a total of 283 serum samples were analysed with the CA 15- ficient (r) was 0.967 (p = < 1 (T 6 ). Figure 4 shows the plotted results from 263 serum samples within the meas- uring range of the Boehringer Mannheim assay. In four laboratories 213 serum samles were analysed for CEA with the Abbott IMx assay and the Boehringer Mannheim. The correlation is represented in figure 5 . The regression equation was: y = 1.136 χ + 0.523 (BM = y and IMx = x) (r = 0.967; p = < 1 (T   6   ) .
Reference values
Reference values based on helathy subjects were determ ined using the Boehringer Mannheim assay. The results were compared with the value on the package insert of the assays. Table 4 shows that all results obtained Tab ') values based on non-malignant lung diseases
2 ) values based on healthy subjects in this study (with the exception of Cyfra 21-1) were below the assigned values. The reference value of Cyfra 21-1 based on non-malignant lung diseases (8.8 μg/l) is significantly higher than the value quoted on the package insert.
CA 125 in gynaecological diseases
The 95th percentile in healthy female blood donors (N = 140) using Enzymun-Test® CA 125 II was 21.8 kU/1. This is substantially lower than the generally accepted reference level of 35 kU/1. Of 41 patients with endometriosis, 28 (68%) had levels above 21.8 kU/1 and 25 patients (61%) had concentrations above 35 kU/1. Levels of CA 125 II up to 295 kU/1 were recorded in patients with endometriosis. In contrast, in patients with benign ovarian cysts (N = 20), 7 (35%) had concentrations above 21.8 kU/1 and only 2 (10%) had levels above 35 kU/1.
Sensitivity of tumour markers in gastrointestinal cancer
In table 5 the 95% reference levels of CEA, CA 19-9 and CA 72-4 are presented as they were determined in this study in healthy individuals (N = 1098) and benign gastrointestinal diseases (N = 103). The sensitivity of these markers at 95% specificity, as determined in this study for normals and patients with benign disease, was calculated in pre-operative samples of patients with colon cancer, pancreatic cancer and gastric cancer. These results are summarized in Tables 6a, b , and c. In colon cancer, CEA is the most sensitive marker for both reference groups: 59% and 44% respectively. The difference in sensitivity with either CA 19-9 or CA 72-4 is highly significant (p = 0.008 and ρ = 5.2 Χ 1(Γ 7 , respectively). The combination of CEA with CA 19-9 increases the sensitivity to 70% using healthy individuals as the reference group (p = 0.02). In comparison with the benign gastrointestinal disease group a small increase is seen by combining CEA with CA 19-9 or CA 72-4. However, this is not significant. In pancreatic cancer, CA 19-9 showed the highest sensitivity, compared with both reference groups (78% and 62%, respecTab. 6 Gastrointestinal cancers. The sensitivity was calculated according to the cut-off based on healthy subjects obtained in this study and the cut-off based on patients with benign gastrointestinal diseases. The number expresses the number of values above the cut-off; in () the percentage elevated values is given. tively with p-values ranging from 7.5 X 10 4 to 4.3 X 10~7). The small increase in sensitivity achieved by combining CA 19-9 with either CEA or CA 72-4 is not significant.
In gastric cancer, CA 19-9 showed the highest sensitivity (44%) compared with healthy individuals, whereas CA 72-4 has the highest sensitivity (31%) compared with the benign disease group. However, these differences in sensitivity between the three markers are not significant. With healthy individuals as the control group, the sensitivity is increased by combining CA 19-9 with either CEA or CA 72-4 (p = 0.03 and p = 0.04, respectively). However, there is no significant difference between the combination CA 19-9 + CEA or CA 72-4 + CEA. With the benign disease group as control, sensitivity is highest in the combination CA 72-4 + CEA but this is not significantly different from the sensitivity of the CA 72-4 determination alone. In 74 out of 110 serum samples from gastric cancer patients, staging was available (tab. 7). The sensitivity of all markers in stage I and II cancer is very low, compared with the healthy control group. When compared with the benign disease group, only CA 19-9 showed elevated levels (6/19) in stage II cancer. In stage III cancer the sensitivity of the three markers is the same for both reference groups. In stage IV, CA 72-4 has the highest sensitivity (59%) as compared with the benign disease group. This is significant when compared with CA 19-9 (p = 0.04), but not when compared with CEA. When the benign disease group is taken as the reference group, only CA 72-4 is stage-dependent (stage III/IV: ρ = 0.04).
Discussion
Quality control and standardisation of tumour marker tests is becoming increasingly important, since it is important, for both patients and physicians, to use the reTab. 7 The number of patients with elevated levels of CEA, CA 19-9 and CA 72-4 in gastric cancer stage 1-IV according to the reference is represented. Values based on healthy subjects obtained in this study and on patients with benign gastrointestinal diseases. The percentage of elevated levels is given between (). suits of these marker tests appropriately, and to avoid uncritical overestimation or premature rejection of their use (9) (10) (11) . The trend toward increasing automation is favorable with respect to reproducibility of test results. Also our results from this multicentre study, using the automatic ES 300 and ES 600 analysers, prove that within a given method highly satisfactory results can be obtained with tumour marker determinations. In 95% of cases, the target intra-assay coefficient of variation of less than 5% was achieved for all markers in serum samples with levels starting at the cut-off level and higher. In 86% of the inter-assay determinations in the institutes using low and high control samples, a target inter-assay coefficient of variation of less than 10% was found (tabs. 1 and 2). Also the results of the interlafopratory survey demonstrate the consistency of the test results of the system used (tabs. 3 and 4; fig. 3 ). Linearity of the test system was already reported to be highly satisfactory (5).
However, it is obvious from figures 4 and 5 that the determination of the same tumour marker using different test systems is not well standardised, even when the same monoclonal antibodies are used, as in the CA 15-3 tests (12) . The problem of standardisation increases when different antibodies are used, as in the CEA test.
Of special clinical interest are the reference levels determined in different institutes compared with the values given by the manufacturer in the package insert. In this study, combining the tumour marker values of healthy individuals as they were determined in 23 institutes, the 95 and 99 percentiles was somewhat lower than given by the manufacturer of Enzymun-Test®. This is again an indication that the system is highly reproducible in different institutes. Only the reference limit of Cyfra 21.1 was found to be somewhat higher in healthy individuals, and this reference limit was definitely higher when patients with benign king disesae were taken as the reference group (in accordance with the manufacturer's insert). To find the correct cut-off in benign lung diseases it will be necessary to use larger groups, including a clear definition of diseases like chronic obstructive lung disease, acute obstructive lung disease, inflammatory lung disease etc. Therefore the sensitivity of CYFRA 21.1 in lung cancer needs further investigation (13) .
CA 125 discriminated well between patients with endometriosis and healthy female donors (14) . In our study using the second generation test of CA 125, the 95th percentile of healthy female donors was distinctly lower (21.8 kU/1) than reported for the original Centocor CA 125 version (35 kU/1).
CEA has long been used in colorectal cancer, and more recently the determination of CA 19-9 was applied in pancreatic cancer (15) (16) (17) . The contribution of the new marker CA 72-4 has been discussed, and its application in gastric cancer has been proposed (18) (19) (20) (21) (22) (23) (24) (25) (26) . We compared the results of these three markers in gastrointestinal cancers in comparison with the cut-off in healthy individuals and in benign gastrointestinal diseases. As expected, a higher cut-off was determined for the three markers using as the reference group patients with benign gastrointestinal diseases (tab. 5). In particular, CA 19-9 showed a much higher cut-off (75 kU/1 versus 21.5 kU/1) for this reference group. In colorectal cancer (including 226 patients with all preoperative stages) CEA appeared to be still the marker of choice, irrespective of the reference group. By combining marker resultswhere one or the other should be elevated -the specificity was decreased. The increase in sensitivity was only significant when the combination of CEA and CA 19-9 was used, as compared with the normal cut-off. This is caused by the low specificity of CA 19-9 in benign gastrointestinal disease. In pancreatic cancer (63 patients) CA 19-9 was the most sensitive marker, as already reported (15 -17) . No significant increase in sensitivity is obtained by combining CA 19-9 and CEA determinations or CA 19-9 and CA 72-4. It has been reported that CA 72-4 has a high sensitivity in gastric cancer (18, 19) . Others, in rather small series, could not confirm this observation, but they used different cut-off levels, i. e. 4 kU/1 (20) and 6 kU/1 (21) . In a larger series, Wobbes et al. used a cut-off of 3 kU/1 and estimated a sensitivity for both CA 72-4 and CA 19-9 (cut-off 37 kU/1) of 34% in a group of 94 patients with gastric carcinoma (22) . In our study, comprising 110 patients, we determined the sensitivity of CA 72-4, CA 19-9 and CEA in comparison with the 95% reference level in normals and in benign gastrointestinal disease from our own investigations. For CEA these reference levels were somewhat lower than is generally accepted (3.4 g/l in normals and 6.2 g/l in benign disease). For CA 19-9 the reference level in normals was lower (21.5 kU/1) but in benign disease we found a high reference level of 75 kU/1. For CA 72-4 the reference level in normals was 4.5 kU/1 and in benign disease 8.9 kU/1. Therefore the sensitivity of these markers does not compare very well with that reported earlier (20^22). However, the problem of standardisation of test results using different test systems has to be kept in mind. Most of the investigations with CA 72-4 and CA 19-9 were performed using the Centocor IRMA test. In comparison with healthy individuals CA 19-9 showed the highest sensitivity (44%), but compared with the benign disease group CA 72-4 was more sensitive (31%). This can be explained by the high reference level of CA 19-9 in the benign disease group. In our calculations the differences in sensitivity were not significant. However, significance was not calculated in the earlier reports (20) (21) (22) . Besides, the cut-off levels chosen in these studies for the different markers resulted in different specificities of the markers. . This is in agreement with our results where a sensitivity for CA 72-4 of 59% was determined in stage IV, which was higher than the sensitivity of CA 19-9 (34%) using the benign disease group as the control. They also stated that the sensitivity of CA 72-4 was stage-dependent, as we also found in our study. We also confirmed that the sensitivity could be increased by combining CA 72-4 and CA 19-9 (in our study only when the healthy controls were taken as the reference group). Other recent data in large patient groups indicated CA 72-4 to be the marker of choice using a cut-off level for CA 72-4 of 3.9 kU/1 at 95% specificity in a group of patients with benign disease of the gastrointestinal tract, including patients with benign liver disease (24) . However, at this 95% specificity the cut-off level for CA 19-9 was very high: 166 kU/1. This could explain the relatively high sensitivity of CA 72-4 (36%) compared with CA 19-9 (21%). At the time of local relapse, or occurrence of distant metastases, the sensitivity of CA 72-4 was 56% (56%) and of CA 19-9 18% (28%). Gartner et al. could not confirm this high sensitivity of CA 72-4 compared with CA 19-9 (25) . But in this study the cut-off value for CA 72-4 was 6.8 kU/1 and for CA 19-9 37 kU/1. Saß et al. calculated again a high sensitivity for CA 72-4 using different cut-off levels for CA 72-4 i. e. 2.5 kU/1 and 10 kU/1 (26) . Very few patients with benign gastrointestinal disease showed levels above 10 kU/1. Probably the reference level of CA 19-9 was fixed at 37 kU/1. They also found CA 72-4 to be clearly stage-dependent, but determined a sensitivity for CA 72-4 of 31% in stage I gastric cancer versus 88% in stage IV.
In conclusion, in the present study we compared the sensitivity of the markers CEA, CA 19-9 and CA 72-4 in gastrointestinal cancer at 95% specificity, using cut-off levels of healthy individuals and patients with benign gastrointestinal disease, according to earlier recommendations by the working group 'Quality control and Standardization of Tumour Marker Tests' under the auspices of the Hamburg Symposia on Tumour Markers (27) . The reference data were obtained in the study and not just taken from the test package inserts. CEA is still the marker of choice in colorectal cancer as is CA 19-9 in pancreatic cancer. In these two types of cancer no increase in sensitivity was registered by combining markers when the benign disease group was taken as the reference group. Therefore it seems sufficient to determine only one marker in these disease groups. In gastric cancer no definite conclusion can be given. The advantage of CA 72-4 could be that the marker is stage-depen-dent and has the highest sensitivity in advanced disease (stage IV) as compared with the benign disease group.
The intra-assay precision, inter-assay precision and interlaboratory survey all proved that Enzymun-Test® gave reliable results for tumour marker tests. From the analytical point of view, this fulfills a further requirement of the previously mentioned working group (27) . Recently, at the Bergmeier conference under the auspices of IFCC, these requirements were discussed for several tumour markers (9, 12) . We believe that in the near future unequivocal analysis and reporting of tumour marker data will be a necessity in order to supply clinicians with relevant information for the care of oncological patients.
rum and plasma and which can be tested in vitro. To prepare for the discussion, everyone had to send a list of his "favorite" drugs to the organizers. Additional lists were also sent by G. Siest, Nancy, France and H. Sine, Indianapolis, USA.
Results and Discussion
At the beginning of the meeting the following criteria were examined in order to select a valid list from the above mentioned "favorite" lists:
-Typical (high) serum concentration -Typical test interference on clinical chemistry methods -How often is the drug used? -Relevance in vivo -Drugs absorbing light at clinical chemistry methods wavelengths
Further background information utilized during the discussion was the 7th edition of the book by Nils Tryding (1) and the proposed Guideline Interference Testing in clinical chemistry by NCCLS (2).
The outcome of the symposium is summarized in table L
